At AstraZeneca, science and patients are at the heart of everything we do and drive us to push the boundaries of what’s possible in cancer care. This week, at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, December 9-12, AstraZeneca, Acerta Pharma, our hematology research and development center of excellence, and MedImmune, our global biologics research and development arm, will present scientific updates from our diverse emerging blood cancer portfolio on five investigational compounds across six types of blood cancer.

This week, and all year long, we’re following the science to develop and deliver innovative new treatment options for blood cancer patients in need as we aim to redefine the cancer treatment paradigm and improve patients’ lives.